BCM
NVET

Bridgeway Capital Management’s Nexvet Biopharma plc Ordinary Shares NVET Stock Holding History

Bridgeway Capital Management’s Portfolio NVET Stock Details NVET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-44,400
Closed -$173K – 1510
2017
Q1 		$173K Hold
44,400
– – ﹤0.01% 1296
2016
Q4 		$163K Hold
44,400
– – ﹤0.01% 1335
2016
Q3 		$185K Hold
44,400
– – ﹤0.01% 1332
2016
Q2 		$206K Hold
44,400
– – ﹤0.01% 1302
2016
Q1 		$146K Hold
44,400
– – ﹤0.01% 1339
2015
Q4 		$151K Buy
+44,400
New +$175K ﹤0.01% 1341

Other funds holding NVET

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KAM
Kassirer Asset Management Toronto, Ontario, Canada $4.07M AUM 49.71% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
SMC
S. Muoio & Co New York $75.7M AUM 42.51% 1-Year Est. Return

Bridgeway Capital Management's NVET Position: Q2 2017 in Review

Bridgeway Capital Management sold out of Nexvet Biopharma plc Ordinary Shares (NVET) in Q2 2017, closing a stake of 44,400 shares — an estimated $173K sold.

Bridgeway Capital Management first reported a position in NVET in Q4 2015 and held it in 6 quarters. The position peaked at $206K in Q2 2016. 20 funds tracked by Wall St. Rank hold NVET as of Q2 2017.

  • Bridgeway Capital Management reported no remaining Nexvet Biopharma plc Ordinary Shares position as of Q2 2017 after selling out during the quarter.
  • Bridgeway Capital Management sold 44,400 Nexvet Biopharma plc Ordinary Shares shares in Q2 2017, an estimated $173K.
  • Bridgeway Capital Management first reported a position in Nexvet Biopharma plc Ordinary Shares in Q4 2015 and held it in 6 quarters.
  • Bridgeway Capital Management's Nexvet Biopharma plc Ordinary Shares position peaked at $206K in Q2 2016.
  • 20 funds tracked by Wall St. Rank held Nexvet Biopharma plc Ordinary Shares as of Q2 2017.

Based on Bridgeway Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.